Overview

A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.

Status:
RECRUITING

Trial end date:
2029-10-01

Target enrollment:

Participant gender:

Summary

This is a phase II randomized study investigating whether a combination maintenance with Cemiplimab and OSE2101 (TEDOPI) could increase ctDNA clearance rate versus standard maintenance therapy in HLA-A2 positive NSCLC patients not progressing after 4 cycles of chemo-immunotherapy.

Phase:

PHASE2

Details

Lead Sponsor:

Fondazione Ricerca Traslazionale

Treatments:

cemiplimab